Acumen Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-55.94	-52.37	-42.86	-100.61	-7.33	-7.69
Depreciation & Amortization	0.18	0.18	0.17	0	0	0
Share-Based Compensation	7.24	6.15	3.06	0.92	0.15	0.17
Other Operating Activities	-2.23	2.98	4.47	81.72	-0.28	0.92
Operating Cash Flow	-50.75	-43.06	-35.15	-17.96	-7.45	-6.82
Capital Expenditures	-0.03	-0.02	-0.16	-0.04	0	0
Change in Investments	-138.92	-171.65	39.35	-104.08	0	0
Investing Cash Flow	-138.95	-171.67	39.19	-104.12	0	0
Share Issuance / Repurchase	130.14	122.23	3.91	169.19	0	0.01
Debt Issued / Paid	28.79	29.52	0	0	0	0
Other Financing Activities	0.09	-	-	31.28	44.68	6.23
Financing Cash Flow	159.01	151.75	3.91	200.47	44.68	6.24
Net Cash Flow	-30.84	-62.98	7.94	78.39	37.23	-0.58
Free Cash Flow	-50.78	-43.08	-35.31	-18	-7.45	-6.82
Free Cash Flow Per Share	-0.85	-0.89	-0.87	-0.90	-17.77	-15.83

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).